Idéal Investisseur
Français English
CAC 40 : Market closed
7 969,42 pts
-0.01%


Last updated : 30/10/2026 - 17h36 (last close)
Last close data
🏠 Home   ➤    Stock news

Amoéba: Dutch Green Light for Large-Scale Trials of the Biofungicide Axpera

Amoéba and its partner Koppert have obtained two large-scale experimental authorizations in the Netherlands for the biofungicide AXPERA, lasting two years. These exemptions granted by the Dutch crop protection authority allow, notably, the consumption of crops produced during these trials.


Amoéba: Dutch Green Light for Large-Scale Trials of the Biofungicide Axpera

Two Experimental Permits for AXPERA Technology

Amoéba has received a large-scale experimental permit that extends the one obtained until spring 2025. The College voor de Toelating van Gewasbeschermingsmiddelen en Biociden (CTGB), the competent Dutch authority, authorizes the use of the biofungicide on crops already covered in 2025 (tomato, cucumber, strawberry, rose, gerbera) as well as on new crops (potato, sugar beet, onion, lettuce, spinach, apple, pear, leek), in greenhouses or in open fields on large areas. Koppert, Amoéba's strategic partner and a global leader in biological solutions, also obtained a large-scale field trial permit with the support of Glastuinbouw Nederland, the main network of entrepreneurs in the Dutch sector. This trial exemption concerns protected crops (cucumber, tomato, bell pepper, eggplant, strawberry) and targets specifically the fight against powdery mildew.

The Netherlands as a Strategic Market for Deployment

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Amoéba identifies the Netherlands as a key market due to its status as a European leader in greenhouse horticulture with over 10,000 hectares of protected crops (tomatoes, cucumbers, strawberries, cut flowers). These crops represent a high economic value and are exploited all year round, allowing regular production cycles for local markets and export. The biofungicide AXPERA targets specifically powdery mildew and downy mildew. A notable feature of these exceptional derogations: unlike usual practices that require the destruction of crops from trials with unapproved products, the CTGB allows the consumption of the fruits and vegetables produced, given the low-risk profile of the product.



Sector Chimie › Biotech industrielle (enzymes, fermentation, biorecyclage, biosourcés)


Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext

Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0,1 millions d'euros
  • Quarterly revenue: 0,1 millions d'euros
  • Net income: -7,4 millions d'euros
  • 6,6 millions d'euros
Guidance from the release
  • Sur la base de ses ressources actuelles, de son plan d'affaires et de la lettre de soutien de son actionnaire de référence, Amoéba estime pouvoir faire face à ses obligations jusqu'au 31 décembre 2026.
Risks mentioned
  • Autorisation définitive d'AXPERA obtenue tardivement (fin juin 2026) après période d'utilisation des produits, affectant les ventes du semestre
  • Monétisation de la plateforme cosmétique dont ni la réalisation, ni le calendrier, ni le montant ne sont acquis à ce jour
  • Besoin de levée de fonds supplémentaire pour assurer continuité d'exploitation jusqu'au 30 septembre 2027 et financer plan de développement
Opportunities identified
  • Autorisation pérenne AXPERA obtenue en France en juin 2026 ouvre la voie à la commercialisation en plusieurs pays européens
  • Accord majeur signé avec Syngenta pour distribution exclusive de la solution en céréales dans 27 pays UE, premiers lancements commerciaux attendus Q3 2028
  • Extension de l'accord de distribution Koppert jusqu'en juin 2031 et potentiel de monétisation de la plateforme cosmétique Willa™ dès 2027
Outlook / guidance
  • Expected revenue: 1,5 millions d'euros
  • Management commentary: Building on the outcomes of the various strategic initiatives undertaken since 2023, Amoéba will be able to leverage the ramp-up of its contracts in the agricultural sector from 2027 onwards to achieve revenue of between €1 million and €2 million.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours